Alle Storys
Folgen
Keine Story von Intercell AG mehr verpassen.

Intercell AG

EANS-Adhoc: Intercell and GSK form strategic alliance to develop and commercialize innovative needle-free patch-based vaccines

  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
New Products
11.12.2009
Vienna (Austria) / London (UK), December 11, 2009 - Intercell and 
GlaxoSmithKline Biologicals SA (GSK) today announced an agreement to 
form a strategic alliance to accelerate the development and 
commercialization of needle-free, patch-based vaccines. The agreement
will include Intercell's candidate vaccine for travelers' diarrhea 
(TD) and an investigational single application pandemic influenza 
vaccine, as well as the use of the patch technology for other 
vaccines in GSK's portfolio.
Under the terms of the agreement, GSK will make an up-front cash 
contribution of EUR 33.6 (USD 49.4) million, in addition to an equity
investment of up to EUR 84 (USD 123.5) million through a staggered 
shareholding purchase option of up to 5 % in Intercell. Included in 
the agreement are Intercell's investigational TD vaccine, currently 
in Phase III, and an investigational single application pandemic 
influenza vaccine in Phase II, as well as other potential future 
patch vaccines.
"This new partnership is combining the forces of Intercell's 
innovative needle-free vaccination program and technologies with a 
vaccine leader's strength in development and commercialization. In 
addition, we can pursue our business strategy of creating significant
shareholder value as an independent company whilst continuing to 
develop one of the most innovative product pipelines in the 
industry," says Gerd Zettlmeissl, Chief Executive Officer of 
Intercell.
"This novel technology has real potential to change the way vaccines 
are delivered in the future. GSK has an extensive portfolio of 
vaccines and we believe needle-free vaccination could offer benefits 
such as simplified administration and increased compliance." said 
Jean Stephenne, President of GSK Biologicals. "This agreement 
demonstrates how, as an integral part of our R&D program, we not only
look at new vaccines but also at alternative approaches to oral and 
intramuscular administration."
Each year, approximately 20 million international travelers develop 
TD while visiting endemic areas in Asia, Africa, and South America. 
Currently, there is no vaccine available to address this medical 
need. GSK and Intercell will collaborate on the TD Vaccine Patch, 
currently in phase III, to commercialize this vaccine once it has 
gained regulatory approval. The agreement will also include a 
collaboration between the two companies to further develop and 
co-market an innovative pandemic influenza vaccination approach.
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG